Antidote.me

A New York City, New York, London, U.K., and Carmel, IN based company developing artificial intelligence to increase efficiency between medical treatment and research by matching clinical trials with patients. Antidote.me was originally launched as TrialReach in 2010 and rebranded to Antidote.me in 2016.

The company uses a partner network made up of 300+ patient advocacy groups, health portals, bloggers, lab and data partners, and social media to refer patients to clinical trials. Its areas of therapeutic focus includes:

• Allergy and Immunology
• Arthritis
• Autoimmune
• Cardiology
• CNS
• Dermatology
• Gastroenterology
• IBS
• Liver disease
• Metabolic
• Ophthalmology
• Rare disease
• Renal
• Respiratory

Antidote Match is the core of Antidote.me' platform. The software works to match trials to patients. The software uses industry standard and custom-designed ontologies with their proprietary algorithms to explore patients eligibility for trials. Through the software, patient's can find studies based on the same indicators, and they can find information on the studies and scientists and treatments involved in the clinical trials.

During the COVID-19 pandemic, Antidote.me offered their Antidote Match platform for free in order to try and speed up the process of connecting possible patients to COVID-19 trials.